| 1. |
Jaffe GJ, Lin P, Keenan RT, et al. Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results[J]. Ophthalmology, 2016, 123(9): 1940-1948. DOI: 10.1016/j.ophtha.2016.05.025.
|
| 2. |
Jaffe GJ, Foster CS, Pavesio CE, et al. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve month results[J]. Ophthalmology, 2019, 126(4): 601-610. DOI: 10.1016/j.ophtha.2018.10.033.
|
| 3. |
Jaffe GJ, Foster CS, Pavesio CE, et al. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results[J]. Ophthalmology, 2020, 127(10): 1395-1404. DOI: 10.1016/j.ophtha.2020.04.001.
|
| 4. |
Liu T, Bi H, Wang X, et al. Macular abnormalities in Chinese patients with uveitis[J]. Optom Vis Sci, 2015, 92(8): 858-862. DOI: 10.1097/OPX.0000000000000645.
|
| 5. |
Branson SV, McClaferty BR, Kurup SK. Vitrectomy for epiretinal membranes and macular holes in uveitis patients[J]. J Ocul Pharmacol Ther, 2017, 33(4): 298-303. DOI: 10.1089/jop.2016.0142.
|
| 6. |
Becker M, Davis J. Vitrectomy in the treatment of uveitis[J]. Am J Ophthalmol, 2005, 140(6): 1096-1105. DOI: 10.1016/j.ajo.2005.07.017.
|
| 7. |
Callaway NF, Gonzalez MA, Yonekawa Y, et al. Outcomes of pars plana vitrectomy for macular hole in patients with uveitis[J]. Retina, 2018, 38(Suppl 1): S41-48. DOI: 10.1097/IAE.0000000000001942.
|
| 8. |
Kurup SK, Fine HF, Thomas T. Whether to ignore the macular hole in a uveitic patient: a discussion of the pros and cons of elective macular surgery in a challenging population[J]. Ophthalmic Surg Lasers Imaging Retina, 2017, 48(12): 956-960. DOI: 10.3928/23258160-20171130-01.
|
| 9. |
Gunzenhauser RC, Greven MA, John VJ. Anterior migration of intravitreal fluocinolone acetonide implants: a case report[J]. Retin Cases Brief Rep, 2022, 16(1): 67-69. DOI: 10.1097/ICB.0000000000000897.
|
| 10. |
Alzaabi M, Taguri AH, Elbarky A. Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule[J/OL]. Am J Ophthalmol Case Rep, 2020, 11(20): 100922[2020-09-11]. https://pubmed.ncbi.nlm.nih.gov/32995665/. DOI: 10.1016/j.ajoc.2020.100922.
|
| 11. |
Mahmud H, Stewart JM. Migration of a fluocinolone acetonide implant (Yutiq) to the anterior chamber and its nonurgent removal[J/OL]. Am J Ophthalmol Case Rep, 2020, 6(20): 100987[2020-11-06]. https://pubmed.ncbi.nlm.nih.gov/33204898/. DOI: 10.1016/j.ajoc.2020.100987.
|
| 12. |
Homayoun T, Kourous R. Scleral fixation of fluocinolone acetonide implant[J/OL]. Am J Ophthalmol Case Rep, 2020, 12(19): 100775[2020-06-12]. https://pubmed.ncbi.nlm.nih.gov/32577584/. DOI: 10.1016/j.ajoc.2020.100775.
|
| 13. |
Jomaa E, Koudsié S, Gontier B, et al. Comparison of available clinical and imaging tools to assess good positioning of a fluocinolone acetonide implant (Iluvien®) in the vitreous cavity after injection[J]. J Fr Ophtalmol, 2023, 46(4): 369-376. DOI: 10.1016/j.jfo.2022.09.034.
|
